人类恶性肿瘤靶向治疗的新希望—CDK12/CDK13  

CDK12/CDK13:New Hope for Targeted Therapy of Human Malignant Tumors

作　　者：陈凯星 武洲英 俞兰 CHEN Kaixing;WU Zhouying;YU Lan(Graduate School of Inner Mongolia Medical University,Hohhot 010000,China;Clinical Medical Research Center/Inner Mongolia Key Laboratory of Gene Regulation of The Metabolic Diseases,Inner Mongolia People's Hospital,Hohhot 010000,China;Institute of Basic Medical Sciences,Inner Mongolia Academy of Medical Sciences,Hohhot 010000,China)

机构地区：[1]内蒙古医科大学研究生学院,呼和浩特010000 [2]内蒙古自治区人民医院临床医学研究中心/内蒙古自治区代谢紊乱疾病基因调控重点实验室,呼和浩特010000 [3]内蒙古医学科学院基础医学研究所,呼和浩特010000

出　　处：《肿瘤防治研究》2024年第5期386-391,共6页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金(82260536,81960449);内蒙古自治区人民医院院内基金(2021YN13)。

摘　　要：细胞周期的更替有赖于细胞周期蛋白依赖性激酶(CDKs),CDKs是重要的蛋白激酶家族,在调节细胞周期和调控基因转录方面具有关键的作用。其中CDK12/CDK13在DNA损伤应答、RNA剪接调控、转录及细胞周期调控等方面至关重要。近年发现CDK12/CDK13在多种癌症中表达异常或发生突变,在癌症发展中扮演着重要角色,已成为近年来研究的热点之一。本篇基于Google Scholar、PubMed和万方数据库,归纳总结了CDK12/CDK13的基本结构、生物学功能、与恶性肿瘤的相关性、以及针对性抑制剂的研究进展进行综述。为后续的靶向治疗新型靶点的研发和机制探讨提供方向,为恶性肿瘤的防治、诊断以及治疗提供新思路。Cell cycle turnover depends on cyclin-dependent kinase(CDKs).CDK is the protein kinase family that plays the key role in regulating cell cycle and gene transcription.CDK12 and CDK13 perform the essential work in DNA damage response,RNA splicing regulation,transcription,and cell cycle regulation.In recent years,CDK12 and CDK13 are expressed abnormally or mutated in a variety of cancers;thus,they are necessary in cancer development and have become popular topics of research.Based on literature from Google Scholar,PubMed,and WanFang database,aspects of CDK12 and CDK13 such as basic structure,biological function,correlation with malignant tumors,and research progress of targeted inhibitors are summarized to provide the direction for the subsequent research of the new targets and mechanisms for targeting therapy while offering a novel approach for the prevention,diagnosis,and treatment of malignant tumors in the future.

关 键 词：细胞周期 癌症 CDK12/CDK13抑制剂 细胞周期蛋白依赖性激酶12 细胞周期蛋白依赖性激酶13 

分 类 号：R730.5[医药卫生—肿瘤]